Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity
Veru Inc VERU
$2.24
▲ +0.90%
(+$0.02)
🗓️ Earnings Next Week
Open
$2.26
Prev Close
$2.22
Day Range
$2.17 – $2.27
52W Range
$2.05 – $7.33
Market Cap
$35.95M
Beta
-1.18
EPS (TTM)
$-0.78
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1990-07-19 |
| Shares Out. | 16,050,000 |
| Website | verupharma.com/ ↗ |
| Phone | 13125959123 |
| Employees | 20 |
| Net Income | -$2.7M |
| Free Cash Flow | -$26.1M |
| Total Assets | $43.1M |
| Total Liabilities | $8.3M |
| Equity | $34.8M |
About Veru Inc
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru Inc is a publicly traded company under the ticker symbol VERU on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)